Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Abbreviated Gadoxetic Acid‐Enhanced MRI for the Detection of Liver Metastases in Patients With Potentially Resectable Pancreatic Ductal Adenocarcinoma

Abbreviated Gadoxetic Acid‐Enhanced MRI for the Detection of Liver Metastases in Patients With... Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer‐related deaths in the United States, making it a major public health concern.1 Surgical resection is the only potentially curative treatment for PDAC. Approximately half of the patients with PDAC present with metastatic diseases, most commonly with liver metastases.2,3 In these patients, the detection and accurate diagnosis of liver metastases are crucial because their presence results in substantial changes in the treatment strategy.4 The National Comprehensive Cancer Network guidelines recommend dynamic contrast‐enhanced computed tomography (CECT) as the preferred imaging modality for the initial evaluation of local resectability and detection of metastases in patients with PDAC.4 Endoscopic ultrasonography and endoscopic retrograde cholangiopancreatography are subsequently performed to confirm the diagnosis. Magnetic resonance imaging (MRI) is not routinely used for staging mainly because of the limited throughput and its limited availability.4Gadoxetic acid‐enhanced MRI enables the acquisition of hepatobiliary phase (HBP) images and has been reported to be useful in detecting liver metastases in patients with PDAC, with better sensitivity than that of CECT.5,6 However, the long examination time may limit the use of gadoxetic acid‐enhanced MRI for patients with PDAC. Abbreviated MRI protocols with limited sequences, which can theoretically be performed in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Magnetic Resonance Imaging Wiley

Abbreviated Gadoxetic Acid‐Enhanced MRI for the Detection of Liver Metastases in Patients With Potentially Resectable Pancreatic Ductal Adenocarcinoma

Loading next page...
 
/lp/wiley/abbreviated-gadoxetic-acid-enhanced-mri-for-the-detection-of-liver-wqmH0F39Oc

References (33)

Publisher
Wiley
Copyright
© 2022 International Society for Magnetic Resonance in Medicine
ISSN
1053-1807
eISSN
1522-2586
DOI
10.1002/jmri.28059
Publisher site
See Article on Publisher Site

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer‐related deaths in the United States, making it a major public health concern.1 Surgical resection is the only potentially curative treatment for PDAC. Approximately half of the patients with PDAC present with metastatic diseases, most commonly with liver metastases.2,3 In these patients, the detection and accurate diagnosis of liver metastases are crucial because their presence results in substantial changes in the treatment strategy.4 The National Comprehensive Cancer Network guidelines recommend dynamic contrast‐enhanced computed tomography (CECT) as the preferred imaging modality for the initial evaluation of local resectability and detection of metastases in patients with PDAC.4 Endoscopic ultrasonography and endoscopic retrograde cholangiopancreatography are subsequently performed to confirm the diagnosis. Magnetic resonance imaging (MRI) is not routinely used for staging mainly because of the limited throughput and its limited availability.4Gadoxetic acid‐enhanced MRI enables the acquisition of hepatobiliary phase (HBP) images and has been reported to be useful in detecting liver metastases in patients with PDAC, with better sensitivity than that of CECT.5,6 However, the long examination time may limit the use of gadoxetic acid‐enhanced MRI for patients with PDAC. Abbreviated MRI protocols with limited sequences, which can theoretically be performed in

Journal

Journal of Magnetic Resonance ImagingWiley

Published: Sep 1, 2022

Keywords: pancreatic adenocarcinoma; liver metastases; MRI; gadoxetic acid

There are no references for this article.